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Abstract
Fanconi Anemia (FA) is a rare autosomal X-linked recessive disorder, characterized by
congenital abnormalities, pediatric bone marrow failure and cancer susceptibility. FA is
caused by biallelic mutation in any one of 22 different genes. The main functions of the
FA-BRCA pathway is the resolution of interstrand crosslinks (ICLs) within the DNA.
The main activating step of the pathway is the monoubiquitination of the proteins
FANCD2 and FANCI. In the first chapter of this dissertation I discuss how methylation
and acetylation affect chromatin architecture and activation of the pathway. In the
second chapter I will discuss the effects of FANCD2 phosphorylation in a DNA
damage-independent, cell cycle-dependent manner. We show that monoubiquitination
of FANCD2 is blocked by phosphorylation and that this phosphorylation acts as a
molecular switch to alter FANCD2 function.
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PREFACE
The following dissertation has been prepared in manuscript format. Chapter 1,
“Modulation of the fanconi anemia pathway via chemically induced changes in
chromatin structure”, was published in Oncotarget and explores how chromatin state is
a key determinant in DNA, in particular changes that occur due to histone post
translational modifications . Chapter 2, “Phosphorylation of FANCD2 regulates its
function in DNA damage independent manner” is ongoing research. This chapter
presents work in which we identified a putative CDK cluster proximal to the site of
monoubiquitination.
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Fanconi anemia (FA) is a rare disease characterized by congenital defects, bone
marrow failure, and atypically early-onset cancers. The FA proteins function
cooperatively to repair DNA interstrand crosslinks. A major step in the activation
of the pathway is the monoubiquitination of the FANCD2 and FANCI proteins,
and their recruitment to chromatin-associated nuclear foci. The regulation and
function of FANCD2 and FANCI, however, is poorly understood. In addition, how
chromatin state impacts pathway activation is also unknown. In this study, we have
examined the influence of chromatin state on the activation of the FA pathway. We
describe potent activation of FANCD2 and FANCI monoubiquitination and
nuclear foci formation following treatment of cells with the histone
methyltransferase inhibitor BRD4770. BRD4770-induced activation of the
pathway does not occur via the direct induction of DNA damage or via the
inhibition of the G9a histone methyltransferase, a mechanism previously proposed
for this molecule. Instead, we show that BRD4770- inducible FANCD2 and FANCI
monoubiquitination and nuclear foci formation may be a consequence of inhibition
of the PRC2/EZH2 chromatin-modifying complex. In addition, we show that
inhibition of the class I and II histone deacetylases leads to attenuated FANCD2
and FANCI monoubiquitination and nuclear foci formation. Our studies establish
that chromatin state is a major determinant of the activation of the FA pathway
and suggest an important role for the PRC2/EZH2 complex in the regulation of
this critical tumor suppressor pathway.
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INTRODUCTION
All organisms are continuously exposed to endogenous and exogenous DNA damaging
agents, including reactive oxygen species and aldehydes from normal metabolic
processes and UV irradiation from sunlight. The timely and accurate repair of DNA
damage is essential for the maintenance of genome stability and organismal survival.
As a consequence, prokaryotic and eukaryotic organisms have evolved complex and
highly orchestrated DNA repair pathways to effectively repair damaged DNA.
Chromatin represents the higher order macromolecular complex of DNA and histone
proteins, and chromatin plasticity has become increasingly recognized as a major
determinant of DNA damage recognition, signaling, and repair [1–3]. The nucleosome
is the fundamental subunit of chromatin and exhibits plasticity via compositional
alteration, translational repositioning, and the posttranslational modification of histone
tails. Histone tails are subject to a wide variety of posttranslational modifications
including acetylation, methylation, phosphorylation, and ubiquitination [4]. Histone
acetylation homeostasis is mediated by histone acetyltransferases (HATs), e.g.
TIP60/KAT5, and deacetylases (HDACs), e.g. HDAC1 and HDAC2. Underscoring the
importance of histone acetylation in DNA repair, key roles for TIP60/KAT5, HDAC1,
and HDAC2 in the maintenance of genome stability have been established [5–7].
Fanconi anemia (FA) is a rare autosomal and X-linked genetic disease characterized by
congenital defects, bone marrow failure, and increased cancer risk in early adulthood
[8]. FA is caused by mutation of any one of 21 genes. The FA proteins function
primarily in the repair of DNA interstrand crosslinks (ICLs), lesions that block the
replication and transcription machineries, which lead to structural and numerical
3

chromosome aberrations if repaired erroneously [8–11]. A central step in the activation
of the FA pathway is the site-specific monoubiquitination of the FANCD2 and FANCI
proteins [12–14]. Monoubiquitinated FANCD2 and FANCI localize to discrete sites
within chromatin where they are hypothesized to promote the recruitment of several
structure-specific endonucleases, including FAN1 (FANCD2-associated nuclease 1)
and FANCQ/ERCC4 [15–18]. While FANCD2 and FANCI function primarily within
chromatin, the contribution of chromatin plasticity, and specifically, the effects of
changes in histone tail post translational modifications, on their activation and function
have yet to be determined. Furthermore, while chromatin remodeling at DNA doublestrand breaks (DSBs) has been extensively studied [1–3], very little is known about the
role of chromatin remodeling in the context of ICL repair.
In this study we have examined the influence of chromatin structure on the activation
of the FA pathway. Specifically, we have examined the effects of several histone
methyltransferase (HMT), demethylase (HDM), and deacetylase (HDAC) inhibitors on
FANCD2 and FANCI monoubiquitination and their assembly into discrete nuclear foci.
We describe potent activation of FANCD2 and FANCI monoubiquitination in
chromatin, and enhanced FANCD2 and FANCI nuclear foci formation, following
cellular exposure to the HMT inhibitor BRD4770. BRD4770-induced activation of the
pathway does not appear to occur via the direct induction of DNA damage perse, or via
the inhibition of the G9a histone methyltransferase, a mechanism previously proposed
for this molecule [19]. In contrast, our results suggest that BRD4770-induced activation
of the pathway may be a consequence of inhibition of PRC2 (Polycomb Repressive
Complex 2) and, specifically, its catalytic HMT EZH2. In addition, we demonstrate that
4

inhibition of class I and II HDACs with trichostatin A (TSA) and vorinostat (SAHA)
leads to attenuated ICL-inducible FANCD2 and FANCI monoubiquitination and
nuclear foci formation. Our results establish that chromatin plasticity, and in particular
the posttranslational modification of histone tails, is a critical determinant in the
activation of the FA tumor suppressor pathway.
RESULTS
Activation of FANCD2 and FANCI monoubiquitination by the HMTi BRD4770.To
explore the effects of global alterations in histone methylation on the activation of the
FA pathway, we exposed the transformed osteosarcoma cell line U2OS and the
nontransformed telomerase (hTERT)- immortalized line BJ-TERT to the HMT
inhibitors (HMTi) BRD4770 and BIX01294 and the HDM inhibitors (HDMi) GSK-J1
and PBIT, and examined FANCD2 and FANCI monoubiquitination. BRD4770 is a Sadenosylmethionine (SAM) mimetic and competitive inhibitor of PRC2/ EZH2 and G9a
[19–21]. BIX01294 is a non-SAM mimetic selective inhibitor of G9a [21]. Treatment
with BRD4770 resulted in a marked increase in FANCD2 and FANCI
monoubiquitination in both U2OS and BJTERT cells, even in the absence of the ICLinducing agent mitomycin C (MMC) (Figure 1A and B, lane 3). Indeed, the ratio of
FANCD2-Ub to FANCD2 (L:S ratio) was higher in cells treated with BRD4770 alone
than in cells treated with MMC alone (Figure 1A and B, compare lanes 2 and 3).
BRD4770-induced activation of FANCD2 monoubiquitination also occurred in a
concentration-dependent manner (Figure 1C). In contrast, no major
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Figure 1: The HMTi BRD4770 induces the monoubiquitination of FANCD2 and
FANCI. (A) and (B), U2OS (A) and BJ-TERT (B) cells were incubated in the absence
(NT) or presence of 10 μM BRD4770, 2.5 μM BIX01294, 5 μM GSK-J1 and 1 μM
PBIT, with (+) and without (-) 200 nM mitomycin C (MMC) for 24 h. Whole-cell
lysates were prepared and immunoblotted with anti-FANCD2, anti-FANCI, and anti-ɑTubulin antibodies. (C) U2OS cells were incubated with the indicated concentrations of
BRD4770 and BIX01294 for 24 h, and whole-cell lysates were immunoblotted with
anti-FANCD2, anti-FANCI, and anti-ɑ-Tubulin antibodies. L:S Ratio, ratio of
monoubiquitinated to nonubiquitinated FANCD2.
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effects on levels of spontaneous or ICL-inducible FANCD2/I monoubiquitination were
observed for the other inhibitors tested, other than a slight increase in the FANCD2/I
L:S ratios following treatment of BJ-TERT cells with GSK-J1 (Figure 1B).
BRD4770 promotes FANCD2 chromatin localization and nuclear foci formation.
Next, we examined the effects of BRD4770 treatment on the localization of FANCD2
to chromatin and its assembly into nuclear foci. Cells were incubated in the absence or
presence of BRD4770, both with and without MMC, and whole-cell (W), soluble
cytoplasmic and nuclear (S), and chromatin-enriched (C) protein lysates were prepared
and analyzed by immunoblotting. We observed greatly elevated levels of
monoubiquitinated FANCD2 and FANCI in the chromatin fraction of cells treated with
BRD4770 alone (Figure 2A, compare lanes 3 and 9). In addition, using
immunofluorescence microscopy (IF), we analyzed FANCD2 nuclear foci formation,
an indicator of the localization of FANCD2 to sites of damaged DNA in chromatin [12,
22], following treatment with BRD4770 alone and following combined treatment with
BRD4770 and MMC. We observed a striking increase in the percentage of nuclei
exhibiting greater than 5 FANCD2 foci in both U2OS and BJTERT cells following
BRD4770 treatment (Figure 2B and Supplementary Figure 1A and B). Levels of
FANCD2 nuclear foci formation in cells treated with BRD4770 alone were comparable
to that observed following MMC treatment (Supplementary Figure 1A and B). These
results identify BRD4770 as a major inducer of FANCD2 monoubiquitination and
nuclear foci formation and strongly suggest that changes in histone methylation status
are a critical determinant in the activation of the FA
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Figure 2: The HMTi BRD4770 induces FANCD2 chromatin localization and
nuclear foci formation. (A) U2OS cells were incubated in the absence (NT) or presence
of 10 μM BRD4770 with (+) and without (-) 200 nM mitomycin C (MMC) for 24 h.
Whole-cell lysates (W) and soluble nuclear and cytoplasmic (S) and chromatin-enriched
(C) fractions were prepared and immunoblotted with anti- FANCD2, anti-FANCI, antiH2A, and anti-ɑ-Tubulin antibodies. (B) U2OS cells were incubated with (+) and
without (-) 200 nM MMC in the absence (NT) or presence of 10 μM BRD4770 for 24
h. Cells were fixed and stained with rabbit polyclonal anti-FANCD2 antibody (green)
and counterstained with DAPI (blue), and the number of nuclei with >5 FANCD2 foci
were scored. At least 300 nuclei were scored for each treatment. Representative
immunofluorescence microscopy images are shown.

9

10

pathway. Consistent with BRD4770 functioning via the modification of chromatin
structure, we observed a distinct change in the staining pattern of the heterochromatin
marker HP1ɑ following BRD4770 treatment (Supplementary Figure 1C).
BRD4770-inducible activation of the FA pathway does not occur via direct
induction of DNA damage, increased expression of the FA core complex, or
changes in cell cycle progression. One possible explanation for BRD4770-induced
activation of FANCD2 and FANCI monoubiquitination and nuclear foci formation is
that BRD4770 induces DNA damage directly. To test this hypothesis, we examined
levels of the phosphorylated H2A variant H2AX (γH2AX), a well-established
biomarker of DNA DSB formation [23], in cells treated with and without BRD4770. No
differences in the number of nuclei exhibiting γH2AX foci were observed between
untreated cells and cells treated with BRD4770, both in the absence or presence of
MMC (Figure 3A and Supplementary Figure 2). Similar results were observed in both
U2OS and BJ-TERT cells (Figure 3A and Supplementary Figure 2). U2OS cells have a
highly unstable karyotype, with recurrent breakage-fusion-bridge cycles most likely
contributing to the elevated spontaneous levels of γH2AX nuclear foci formation
observed in these cells (Supplementary Figure 2). While we observed a faint γH2AX
signal for cells treated with BRD4770 alone via immunoblotting, this level was
markedly lower than that observed following exposure to the topoisomerase type II
inhibitor etoposide (VP-16), a well known inducer of DNA DSBs, and no different to
that observed following GSK-J1 treatment (Figure 3B). We also examined levels of
RPA S4/8 phosphorylation, a marker of single-stranded DNA [24], following BRD4770
exposure. While MMC treatment led to a strong increase in levels of RPA
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Figure 3: BRD4770-induced activation of the FA pathway does not occur via the
direct induction of DNA damage or altered cell cycle progression. (A) BJ-TERT
cells were incubated with (+) and without (-) 200 nM mitomycin C (MMC) in the
absence (NT) or presence of 10 μM BRD4770 for 24 h. Cells were fixed and stained
with mouse monoclonal anti-γH2AX antibody and counterstained with DAPI, and the
number of nuclei with >5 γH2AX foci were scored. At least 300 nuclei were scored for
each treatment and this experiment was performed three times with similar results. Error
bars represent the standard errors of the means from three independent experiments. (B)
BJ-TERT cells were incubated with (+) and without (-) 0.4 μM etoposide (VP-16), in
the absence or presence of 10 μM BRD4770, 5 μM GSK-J1 and 2.5 μM BIX01294, for
24 h. Whole-cell lysates were immunoblotted with anti-γH2AX and anti-PCNA
(loading control) antibodies. (C) U2OS cells were incubated in the absence (NT) or
presence of 200 nM MMC or 5 and 10 μM BRD4770 for 24 h. Whole-cell lysates were
prepared and immunoblotted with anti-FANCD2, anti-FANCA, anti-UBE2T, antiUSP1, anti-CHK1 pS345, anti-RPA, anti-RPA pS4/8, and anti-ɑ-Tubulin antibodies.
L:S Ratio, ratio of monoubiquitinated to nonubiquitinated FANCD2; RBI, relative band
intensity. (D) U2OS cells were incubated in the absence or presence of 2, 5, and 10 μM
BRD4770 for 24, 48, or 72 h. Cells were fixed in ice-cold ethanol, stained with
propidium iodide, and analyzed by flow cytometry. Cell cycle stage distributions were
determined using FlowJo v10.2.
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pS4/8, no increase in levels above that of untreated cells was observed for BRD4770
(Figure 3C). We also examined the effects of BRD4770 treatment on levels of the FA
core complex proteins FANCA and UBE2T/FANCT. UBE2T/FANCT is the FANCD2
E2 ubiquitin-conjugating enzyme [25]. Levels of both proteins decreased following
BRD4770 treatment (Figure 3C). Decreased levels of FANCA were also observed
following exposure of HCT116 p53+/+ and p53-/- cells to BRD4770 (see
Supplementary Figure 3D). Similarly, we observed a reduction in levels of the USP1
de-ubiquitinating enzyme following BRD4770 treatment (Figure 3C). Concomitant
reductions in the levels of FANCA, UBE2T/FANCT, and USP1 cannot explain the
observed BRD4770-induced FANCD2 and FANCI monoubiquitination and nuclear
foci formation.
We observed an increase in levels of phosphorylated CHK1 S345 following treatment
with BRD4770, albeit to a lesser extent than that observed following MMC treatment
(Figure 3C). Finally, we examined the effects of BRD4770 treatment on cell cycle
progression. Following exposure to BRD4770 for 24 h, we observed an increase in the
percentage of cells in S-phase at all concentrations of BRD4770 examined (Figure 3D).
However, following exposure to BRD4770 for 48 and 72 h, where maximal induction
of FANCD2 and FANCI monoubiquitination was observed (see Figure 4B), the cell
cycle stage profiles did not differ substantially from that of untreated cells (Figure 3D).
Taken together, these results argue that BRD4770-induced activation of the FA pathway
does not appear to be a consequence of direct induction of DNA damage, alterations in
expression of the FANCD2 core monoubiquitination proteins, or major changes to cell
cycle progression.
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BRD4770-induced activation of the FA pathway may occur via inhibition of the
PRC2 complex BRD4770 is a SAM mimetic and a structural analogue of BIX01338, a
non-selective HMT inhibitor with similar IC50 values against the G9a and SUV39H1
HMTs [19–21]. Therefore, we next treated U2OS cells with varying concentrations of
BIX01338 to determine if we would observe activation of the FA pathway, similar to
that observed for BRD4770. Surprisingly, we did not observe any appreciable induction
of FANCD2 or FANCI monoubiquitination following treatment with BIX01338 for
acute (24 h) (Supplementary Figure 3A) or extended periods (up to 10 d) (results not
shown). BRD4770 is a methyl ester analogue of BRD9539, and previous experiments
with BRD9539 have shown that it exhibits specificity for G9a and PRC2 (Polycomb
Repressive Complex 2) [19]. EZH2 is the catalytic HMT of PRC2, and catalyzes the
deposition of the transcriptionally repressive mark H3K27me3 [26]. Therefore, to
determine if BRD4770-induced activation of FANCD2 monoubiquitination might be a
specific consequence of G9a and/or EZH2 inhibition, we treated cells with the DZNep
and UNC0646 HMT inhibitors: DZNep treatment has been reported to lead to cellular
depletion of EZH2 [27], while UNC0646 is a potent inhibitor of G9a [28]. We observed
modest induction of FANCD2 and FANCI monoubiquitination following exposure to 2
and 4 μM DZNep (Figure 4A). Considerable cell toxicity was observed at 10 μM
DZNep (results not shown). Under these conditions, we did not observe a decrease in
levels of EZH2 expression. However, reduced levels of EZH2 were observed following
incubation with DZNep, and BRD4770 to a lesser extent, for 4 and 8 days
(Supplementary Figure 3B). In contrast to DZNep, no induction of FANCD2/I
monoubiquitination was observed
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Figure 4: BRD4770-induced activation of the FA pathway may occur via inhibition
of the PRC2 complex. (A) U2OS cells were incubated in the absence (NT) or presence
of BRD4770, DZNep, UNC0646, and DZNep and UNC0646 combined (4 μM each) for
24 h. Whole-cell lysates were prepared and immunoblotted with anti-FANCD2, antiFANCI, anti-EZH2, and anti-ɑ-Tubulin antibodies. (B) U2OS cells were incubated in
the absence or presence of 2, 5, and 10 μM BRD4770 for 24, 48, or 72 h. Whole-cell
lysates were prepared and immunoblotted with anti-FANCD2, anti-FANCI, anti-CHK1
pS345, anti-EZH2, anti-H3K27me3, and anti-ɑ-Tubulin antibodies. L:S Ratio, ratio of
monoubiquitinated to nonubiquitinated FANCD2; RBI, relative band intensity.
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following treatment with UNC0646, and combined DZNep/UNC0646 treatment
resulted in considerable cell death (Figure 4A and results not shown). Consistent with
these findings, we also observed a modest yet statistically significant increase in
FANCD2 nuclear foci formation in cells treated with DZNep and not with UNC0646
(Supplementary Figure 3C). We note that the degree of DZNep-induced FANCD2/I
monoubiquitination was experimentally variable, most likely a consequence of its
pleiotropic nature. To further explore the potential role of EZH2 and H3K27me3 in
BRD4770-inducible FANCD2/I monoubiquitination, we exposed U2OS cells to
BRD4770 for 24, 48, and 72 h and examined levels of EZH2 and H3K27me3 (Figure
4B). We observed reductions in levels of H3K27me3 following treatment with higher
concentrations of BRD4770 for 72 h, when induction of FANCD2 monoubiquitination
was maximal (Figure 4B). Under the same conditions, we did not observe any
significant reductions in EZH2 levels (Figure 4B). Similarly, we also observed a modest
reduction in levels of H3K27me3 in HCT116 p53-/- cells treated with BRD4770 for 24
h and a more pronounced reduction in HeLa cells treated with BRD4770 for 72 h
(Supplementary Figures 3D and 3E). We again observed induction of CHK1 pS345
upon exposure to higher concentrations of BRD4770 for extended periods (Figure 4B).
EPZ-6438-mediated inhibition of PRC2/ EZH2 leads to activation of FANCD2
monoubiquitination. To further analyze the role of PRC2 and EZH2 in the activation
of the FA pathway, cells were treated with EPZ-6438, an EZH2-specific inhibitor [29,
30], and FANCD2 and FANCI monoubiquitination and nuclear foci formation were
analyzed. In MCF10A cells, a spontaneously-immortalized, nontransformed, mammary
epithelial line, EPZ-6438 treatment led to a pronounced increase in FANCD2 and
18

FANCI protein levels, FANCD2 and FANCI monoubiquitination, and FANCD2
nuclear foci formation (Figure 5A and Supplementary Figure 4). Interestingly, EPZ6438 treatment led to an increase in levels of EZH2, possibly a cellular response to
chemical inhibition of EZH2, and an overall reduction in levels of H3K27me3 (Figure
5A). EPZ-6438 treatment also resulted in increased FANCD2 monoubiquitination in
isogenic HCT116 p53+/+ and p53-/- cells (Figure 5B) and HeLa cells (Figure 5C). In
contrast to MCF10A, HeLa, and HCT116, we did not detect increased FANCD2
monoubiquitination in U2OS cells treated with EPZ-6438 (results not shown). Taken
together, our results suggest that BRD4770-induced activation of the FA pathway may
occur via inhibition of the PRC2 complex, and specifically EZH2 HMT activity, and a
consequent decrease in levels of H3K27me3.
Inhibition of class I and II HDACs attenuates activation of the FA pathway To
investigate the influence of histone acetylation state on the activation of the FA pathway,
we next examined the effects of the class I and II HDAC inhibitors trichostatin A (TSA)
and vorinostat (SAHA) on FANCD2 and FANCI monoubiquitination and nuclear foci
formation. Interestingly, for HeLa cells, we did not observe any appreciable differences
in the levels of spontaneous or ICL-inducible FANCD2 or FANCI monoubiquitination
when cells were treated with TSA or SAHA (Figure 6A and 6B). In contrast, when BJTERT cells were treated with TSA or SAHA, we observed a marked reduction in the
levels of ICL-inducible FANCD2 and FANCI monoubiquitination (Figure 6C and D).
TSA and SAHA treatment led to a reduction in ICL-inducible CHK1 S345
phosphorylation in both lines examined
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Figure 5: Activation of FANCD2 monoubiquitination following treatment with the
EZH2 inhibitor EPZ-6438. (A-C) MCF10A (A), HCT116 p53+/+ and p53-/- (B), and
U2OS (C) cells were treated with the indicated concentrations of the EZH2-specific
inhibitor EPZ-6438 for 24 h (A and B) or 24, 48, and 72 h (C). Whole-cell lysates were
prepared and immunoblotted with the indicated antibodies. L.E., light exposure; D.E.,
dark exposure; L:S Ratio, ratio of monoubiquitinated to nonubiquitinated FANCD2;
RBI, relative band intensity.
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(Figure 6). In contrast, incubation with TSA and SAHA did not lead to any observable
changes in levels of ICL-inducible CHK2 pT68 (Figure 6). We observed a
concentration-dependent increase in the levels of H4K16ac following treatment with
TSA and SAHA confirming their inhibition of histone deacetylation (Figure 6). We also
observed a reduction in spontaneous and ICL-inducible FANCD2 nuclear foci
formation in both HeLa and BJ-TERT cells treated with TSA or SAHA (Figure 7A–
7D). Consistent with our immunoblotting results, this effect was particularly striking for
BJ-TERT cells with a lesser effect observed for HeLa cells (Figure 7A–7D). The FA
pathway is a major determinant of cellular sensitivity to ICL-inducing agents. Therefore
we next examined if treatment with HDAC I and II inhibitors would sensitize cells to
the cytotoxic effects of MMC. Indeed, even at the low concentrations of inhibitors
examined, treatment with the HDAC I and II inhibitors sodium butyrate (NaB) and TSA
sensitized BJ-TERT cells to the cytotoxic effects of MMC over a range of MMC
concentrations (Figure 8A and B). In contrast, treatment with nicotinamide (NAM), an
inhibitor of the NAD+ (nicotinamide adenine dinucleotide)-dependent sirtuin (class III)
family of HDACs, did not impact cellular sensitivity to MMC (Figure 8C). Taken
together, our results indicate that HDAC1 and HDAC2 positively regulate activation of
the FA pathway and that cellular sensitivity to ICL-inducing agents, which are widely
used in cancer chemotherapy, may be increased via HDAC1/2 inhibition.
DISCUSSION

In this study, we have established that chromatin state is an important determinant in
the activation of the FA pathway. Specifically, we have established that treatment with
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Figure 6: Inhibition of class I and II HDACs attenuates FANCD2 and FANCI
monoubiquitination in BJ-TERT cells. (A) and (B), HeLa cells were pre-treated with
the indicated concentrations of trichostatin A (TSA) (A) or vorinostat (SAHA) (B) for
4 h, followed by co-incubation with (+) and without (-) 200 nM MMC for a further 20
h. Whole-cell lysates were prepared and immunoblotted with anti-FANCD2, antiFANCI, anti-CHK1 pS345, anti-CHK2 pT68, anti-H4K16ac, and anti-ɑ-Tubulin
antibodies. (C) and (D), BJ-TERT cells were treated identically to that described for
HeLa cells above. L:S Ratio, ratio of monoubiquitinated to nonubiquitinated FANCD2.
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the HMTi BRD4770 and inhibition of the class I and II HDACs strongly impacts
activation of the FA pathway. BRD4770 was recently discovered in a focused screen of
a 2-substituted benzimidazole library [19]. While in in vitro biochemical assays,
BRD9539, the carboxylic acid derivative of BRD4770, effectively inhibited both G9a
and PRC2/EZH2 in a concentration-dependent manner, these studies concluded that
BRD4770 functions primarily via the inhibition of G9a [19]. However, in our
experiments, while BRD4770 robustly promoted FA pathway activation, several G9aspecific inhibitors - including BIX01294 and UNC0646 - failed to promote FA pathway
activation. Our results suggest that BRD4770 does not act primarily via G9a inhibition,
and that G9a does not play a significant role in the regulation of the FA pathway.
Instead, our findings suggest that BRD4770 may exert its cellular effects, at least in part,
via the inhibition of PRC2/EZH2, and that PRC2/EZH2 may play an important role in
the regulation of the activation of the FA pathway. Several findings support this model:
Exposure to BRD4770 resulted in reduced levels of H3K27me3 - the transcriptionally
repressive mark deposited by PRC2/EZH2 [26] - in several cell models. Modest
activation of FANCD2 monoubiquitination and nuclear foci formation was observed
following treatment with the PRC2/EZH2 inhibitor DZNep [27]. However, while
DZNep was initially reported to be selective for PRC2/EZH2 [27], as a Sadenosylhomocysteine hydrolase inhibitor, DZNep can also affect global histone
methylation patterns [31]. This led us to examine the effects of inhibition of EZH2 with
the SAM-competitive inhibitor EPZ-6438. EPZ- 6438 is a potent and selective EZH2
inhibitor with an inhibition constant (Ki) of 2.5 nM. EPZ-6438 is 35-fold and >4,500fold more selective for EZH2 than EZH1 and 14 other HMTs
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Figure 7: Inhibition of class I and II HDACs attenuates FANCD2 nuclear foci
formation. (A) and (B), HeLa cells were treated with the indicated concentrations of
trichostatin A (TSA) (A) or vorinostat (SAHA) (B) in the absence (NT) or presence
(MMC) of 200 nM mitomycin C (MMC) for 24 h. Cells were fixed and stained with
rabbit polyclonal anti-FANCD2 antibody and counterstained with DAPI, and the
number of nuclei with >5 FANCD2 foci were scored. *, P < 0.05; **, P < 0.01; ***, P
< 0.001, with comparison to untreated cells. (C) and (D), BJ-TERT cells were treated
identically to that described for HeLa cells above. At least 300 nuclei were scored for
each treatment and these experiments were performed three times with similar results.
Error bars represent the standard errors of the means from three independent
experiments.
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examined [32]. In four out of five lines examined in this study, EPZ-6438 treatment led
to an increase in levels of FANCD2 monoubiquitination. The mechanism(s) by which
inhibition of PRC2/EZH2 and decreased global levels of H3K27me3 would lead to
activation of the FA pathway remain to be clearly elucidated. Recent studies in the
silkworm Bombyx mori have shown that PRC2-mediated H3K27me3 increases
following exposure to UV irradiation [33]. One possibility is that, upon exposure to
DNA damaging agents, transcription may need to be halted at loci that have incurred
DNA damage. An inability to catalyze H3K27me3 and arrest transcription could lead
to the formation of co-transcriptional RNA-DNA hybrids (R-loops). An important role
for the FA proteins in the repair of R-loops has recently been established [34, 35].
However, our γH2AX and RPA pS4/8 results strongly suggest a DNA damageindependent mode of action for BRD4770. An alternative hypothesis is that BRD4770
treatment - possibly via both G9a and PRC2/ EZH2 inhibition - leads to the general
establishment of a transcriptionally permissive chromatin state, which leads to the
recruitment of factors that promote homologous recombination (HR) DNA repair, such
as FANCD2 and FANCI [13, 36]. Consistent with this hypothesis, Aymard et al have
recently shown that HR factors are enriched at transcriptionally active chromatin [37].
It is important to note, however, that BRD4770-induced activation of the FA pathway
most likely does not occur solely via the inhibition of PRC2/EZH2: BRD4770 induces
FANCD2/I monoubiquitination more robustly than the EZH2-specific inhibitor EPZ6438, and EPZ- 6438 treatment results in more pronounced decreases in levels of
H3K27me3. Therefore, other mechanisms are likely to contribute to the observed effects
of BRD4770. In our study, we also detected

28

Figure 8: Inhibition of class I and II HDACs sensitizes cells to the cytotoxic effects
of mitomycin C. BJ-TERT cells were exposed to the indicated concentrations of
mitomycin C (MMC) in the absence or presence of (A) 5 mM sodium butyrate (NaB),
(B) 331 nM trichostatin A (TSA), or (C) 10 mM nicotinamide (NAM) and cellular
proliferation was determined using the CellTiter 96® AQueous One Solution Cell
Proliferation (MTS) assay. Error bars represent the standard errors of the means from
three independent experiments.
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increased phosphorylation of CHK1 S345 following BRD4770 exposure, indicating
activation of the ATR-CHK1 checkpoint-signaling pathway. Numerous studies have
indicated an important role for this pathway in signaling aberrant changes in chromatin
structure [38–40]. One possibility is that BRD4770-induced changes in chromatin state
lead to activation of ATR, phosphorylation of CHK1 and
monoubiquitination of FANCD2, leading to activation of the intra-S-phase checkpoint.
These findings are consistent with a large body of evidence linking the ATR-CHK1
signaling pathway to the activation of the FA pathway [41–44]. However, while
BRD4770 treatment for 24 h did lead to an accumulation of cells in S-phase, exposure
to BRD4770 for longer periods - when levels of phosphorylated CHK1 S345 and
monoubiquitinated FANCD2 were maximal - did not appear to result in an overt Sphase arrest. Further experiments will be required to determine the relationship between
changes in chromatin state, activation of the ATR-CHK1-FANCD2 axis and
maintenance of the intra-S-phase checkpoint.
Here, we have also established that chemical inhibition of class I and II HDACs leads
to attenuation of FANCD2 and FANCI monoubiquitination in BJ-TERT cells, with a
less pronounced effect in HeLa cells, and significant reductions in FANCD2 nuclear
foci formation in both HeLa and BJ-TERT cells. FANCD2/I monoubiquitination and
nuclear foci are not strictly coupled: Usp1-/- murine cells exhibit increased Fancd2
monoubiquitination in the absence of nuclear foci formation [45]. Thus, under the
conditions examined, our findings point to an important role for histone deacetylation
in facilitating the efficient activation of the FA pathway. Previous studies in the budding
yeast S. cerevisiae, have shown that valproic acid (VPA), a class I and II HDACi,
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inhibits Mec1 (orthologue of human ATR) signaling [46]. This is consistent with our
observation of reduced ICL-inducible CHK1 S345 phosphorylation following HDAC
inhibition with SAHA and TSA. Taken together with our BRD4770 findings, our results
indicate that the ATR-CHK1 signaling pathway responds to changes in chromatin
structure, and that phosphorylation and activation of CHK1 correlates with
monoubiquitination and activation of FANCD2.
Several studies have established that, during the very early stages of DSB repair seconds to minutes - a transient repressive chromatin state is first established,
characterized by the spreading of HP1 and H3K9me2/3 [47]. The multisubunit NuRD
repressor complex is rapidly recruited to sites of DNA damage where it promotes
histone deacetylation and chromatin remodeling [48–50]. This may be necessary to
restrict transcription in the immediate vicinity of the damaged site and to promote the
recruitment of repair factors [47]. A failure to rapidly establish this transient repressive
chromatin state would be predicted to lead to inefficient activation of DNA repair
pathways, as we have observed following ICL treatment and HDAC inhibition. In
contrast, a failure to catalyze H3K27me3 upon exposure to BRD4770 or EPZ-6438 may
lead to persistent, constitutively open/relaxed chromatin, which in turn may promote the
inadvertent activation of repair mechanisms, as previously shown [51].
In summary, our results establish that chromatin state is an important determinant of the
activation of the FA pathway. Our findings also suggest that combination chemotherapy
comprising ICL-inducing agents and HDAC inhibitors may be an effective strategy for
certain cancers. Recent studies have identified three functional modules within the FA
core complex: the FANCB-FANCL-FAAP100 module, which provides the essential
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monoubiquitination catalytic activity, and the FANCA-FANCG-FAAP20 and FANCCFANCE-FANCF modules, which are thought to promote the recruitment of the core
complex to chromatin [52, 53]. The majority of FA patients harbor mutations in the
FANCA and FANCG genes, and FANCD2/I monoubiquitination is defective in >95%
of FA patients [54]. Based on our findings, it is conceivable that the chromatin
recruitment of the monoubiquitination catalytic module could be promoted via chemical
modification of chromatin state, raising the prospect of epigenetics-based therapeutic
approaches for certain FA complementation groups.
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MATERIALS AND METHODS
Cell culture
The osteosarcoma cell line U2OS, the cervical carcinoma cell line HeLa, and the
hTERT-immortalized BJ-TERT cells were grown in DMEM supplemented with 15%
v/v fetal bovine serum, 2 mM L-glutamine, 50 U/mL penicillin, and 50 μg/mL
streptomycin. HCT116 p53+/+ and p53-/- cells were grown in McCoy’s 5A medium
containing the same supplements [55]. MCF10A mammary epithelial cells were grown
in DMEM F12 supplemented with 5% v/v horse serum, 20 ng/ml epidermal growth
factor, 0.5 mg/ml hydrocortisone, 100 ng/ml cholera toxin, 10 μg/ ml insulin, 2 mM Lglutamine, 50 U/mL penicillin, and 50 μg/mL streptomycin.
Chemicals
The structures of all chemicals used in this study are shown in Supplementary Figure 5.
The following chemicals were used: BRD4770 (histone methyltransferase inhibitor VI)
(C25H23N3O3) (382194; EMD Millipore), BIX01294 (C28H38N6O2.3HCl.xH2O) (B9311;
Sigma), GSK-J1 (histone lysine demethylase inhibitor VII) (C22H23N5O2) (420204; EMD
Millipore), PBIT (histone lysine demethylase inhibitor IX) (C14H11NOS) (505299; EMD
Millipore), UNC0646 (C36H59N7O2) (SML0633; Sigma), BIX01338 (C32H24F3N 3O6.xH2O)
(B5313; Sigma), DZNep (3-Deazaneplanocin A) (C12H14N4O3) (13828; Cayman
Chemical), EPZ-6438 (Tazemetostat) (C34H44N4O4) (S7128; Selleckchem), SAHA
(Vorinostat) (C14H20N2O3) (SML0061; Sigma), Trichostatin A (TSA) (C17H22N2O3)
(T1952; Sigma), Mitomycin C (MMC) (C15H18N4O5) (BP25312; Fisher Scientific), and
Etoposide (VP-16) (C29H32O13) (E1383; Sigma).
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Immunoblotting and antibodies
For immunoblotting analysis, cell pellets were washed in PBS and lysed in 2% w/v
SDS, 50 mM Tris-HCl, 10 mM EDTA. Proteins were resolved on NuPage 3-8% w/v
Tris- Acetate or 4-12% w/v Bis-Tris gels (Invitrogen) and transferred to polyvinylidene
difluoride (PVDF) membranes. The following antibodies were used: mouse monoclonal
sera against γH2AX (05-636; Millipore), HDAC1 (5356; Cell Signaling), HDAC2
(5113; Cell Signaling), HP1α (05-689; Millipore), PCNA (sc-56; Santa Cruz
Biotechnology), RPA (NA18; Calbiochem), and α-tubulin (MS-581-PO; Neomarkers),
rabbit monoclonal serum against CHK1 pS345 (2348; Cell Signaling), and rabbit
polyclonal sera against CHK2 pT68 (2661; Cell Signaling), EZH2 (5246S; Cell
Signaling), FANCA (ABP6201; Cascade), FANCD2 (NB100-182; Novus Biologicals),
FANCI (A301-254A; Bethyl Laboratories), H2A (07-146; Millipore), H3K27me3
(9733P; Cell Signaling), H4K16ac (07-329; Millipore), RPA pS4/8 (A300-245A;
Bethyl), USP1 (a kind gift from Tony T. Huang, New York University), and UBE2T
(A301-874A; Bethyl).

Immunofluorescence microscopy
For immunofluorescence microscopy (IF) analysis, cells were seeded in 4-well
tissue culture slides (BD Falcon) in the presence or absence of drug(s) for 24 h. Soluble
cellular proteins were pre-permeabilized with 0.3% v/v Triton X-100 and cells were
fixed in 4% w/v paraformaldehyde and 2% w/v sucrose at 4°C followed by
permeabilization in 0.3% v/v Triton X-100 in PBS. Fixed cells were blocked for 30
minutes in antibody dilution buffer (5% v/v goat serum, 0.1% v/v NP-40, in PBS) and
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incubated with primary antibody for 1 h. Cells were washed three times in PBS, as well
as permeabilization buffer, and incubated for 30 min at room temperature with an Alexa
Fluor 488-conjugated secondary antibody and the slides were counterstained and
mounted in vectashield plus 4’6-diamidine-2-phenylindole dihydrochloride (DAPI)
(Vector Laboratories). Nuclear foci were scored using a Zeiss AxioImager.A1 upright
epifluorescence microscope with AxioVision LE 4.6 image acquisition software.
Primary antibodies used for IF were anti-FANCD2 (NB100-182; Novus Biologicals),
anti-FANCI (A300- 212A; Bethyl Laboratories), and anti-γH2AX (05-636; Millipore).
Statistical significance was determined using paired two-tailed Student’s t-test analysis.
Chromatin fractionation
Cells were plated at density of 3 x 106 cells in 15 cm2 dishes. The following day, cells
were treated with 200 nM MMC for 24 h. Cells were harvested and resuspended in icecold PBS. A portion of the pellet was retained as a whole cell lysate (W). The remaining
pellet was lysed on ice in cytoskeletal buffer (CSK) (300 mM Sucrose, 100 mM NaCl,
3 mM MgCl2, 0.5% v/v Triton-X-100, 1 mM EGTA, 10 mM PIPES, pH 6.8). The
supernatant, containing soluble cytoplasmic and nuclear proteins, was collected as the
soluble fraction (S). The remaining pellet, containing chromatin-associated and nuclear
insoluble proteins (C), and the whole-cell lysate pellet, were lysed in 2% SDS lysis
buffer with sonication for 10 s at 10% amplitude using a Fisher Scientific Model 500
Ultrasonic Dismembrator.
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Cell proliferation assay
Cells were plated at a density of 10,000 cells/well in 96-well dishes, incubated in the
absence or presence of drug(s) for 48 h. CellTiter 96® AQueous One Solution Reagent
(MTS) (Promega) was added directly to the wells, incubated for a further 2 h, and the
absorbance at 490 nm was measured using a 96-well Bio-Rad 680 microplate reader.
Cell-cycle analysis
Cells were plated at a density of 1x106 cells in 10 cm2 dishes. The following day, cells
were incubated in the absence or presence of 2, 5, and 10 μM BRD4770 for 24, 48, and
72 h. Cells were resuspended in 0.1 mL PBS and fixed by adding 1 mL ice-cold
methanol. Cells were washed in PBS and incubated in 50 μg/mL propidium iodide (PI)
(Sigma) and 30 U/mL RNase A for 10 min at 37°C, followed by analysis using a BD
FACSVerse flow cytometer. The percentages of cells in G1, S, and G2/M were
determined by analyzing PI histograms with FlowJo V10.2 software.
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Abstract
Fanconi anemia (FA) is a rare genetic disease characterized by early onset bone
marrow failure, congenital defects and increased cancer susceptibility. FA is
caused by mutation in any one of twenty two different genes. The main function of
the proteins encoded by these genes is to resolve interstrand crosslinks (ICL)
within DNA. ICLs present direct physical blocks to DNA replication. Upon
induction of an ICL, a core complex of proteins will come together to create a
multi-subunit ubiquitin ligase, catalyzes the monoubiquitination of FANCD2 and
FANCI, thereby activating these two proteins and initiating ICL repair. In
addition to monoubiquitination, FANCD2 and FANCI are known to be
phosphorylated. To date, all known phospho-sites on FANCD2 and FANCI are
phosphorylated only in the presence of DNA damage. These sites have been well
characterized and their respective kinases have been identified. Our lab has found
a novel phospho-cluster on FANCD2. This cluster is phosphorylated in a DNA
damage independent fashion. The phosphorylation appears to be cell cycle specific,
being at its peak in S phase. We have identified three candidate residues, proximal
to K561, that may be the site of this phosphorylation. There is strong evidence that
the kinase responsible for this phosphorylation is a cyclin dependent kinase (CDK).
Phosphorylation at these sites abrogates FANCD2 monoubiquitination while
dephosphorylation promotes monoubiquitination. Our data suggests that this
phosphorylation may be acting as a “molecular switch” to activate FANCD2s
function during DNA replication.
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Introduction
Fanconi anemia (FA) is a rare, X-linked and autosomal recessive genetic disorder.
Patients suffer from congenital abnormalities, pediatric bone marrow failure and cancer
susceptibility. FA is caused by a biallelic mutation in any one of twenty two different
genes (FANCA, -B, -C, -D1/BRCA2, -D2, -E, -F, -G, -I, -J/BRIP1, -L, -M, -N/PALB2, P/SLX4, O/RAD51C, Q/ERCC4, R/RAD51, S/BRCA1, T/UBE2T,-U/XRCC4,-V/REV7,W/RFWD3)[1-5]. These proteins function cooperatively in the FA-BRCA pathway to
resolve interstrand crosslinks (ICL) within DNA. ICLs present direct physical blocks to
DNA synthesis and are a cause of chromosomal instability. Upon the induction of an
ICL a core complex of proteins, FANCA/B/C/E/F/G/L/T come together to form a
multisubunit ubiquitin ligase. With the help of FANCM, FAAP100/24/20 and MHF1/2,
the core complex will be recruited to the ICL and promote the monoubiquitination of
FANCD2 and FANCI[3, 6, 7]. The monoubiquitination of FANCD2 and FANCI is a
key activating step in the pathway; a step is absent in over 90% of FA patients. Upon
its monoubiquitination FANCD2 and FANCI will work to recruit downstream proteins
that will resolve the ICL in a homologous recombination (HR) mediated process[6, 810]. Without the FA pathway the ICL will be resolved in an error prone process known
as non-homologous end joining (NHEJ), resulting in extensive DNA damage[11, 12].
In addition to monoubiquitination, FANCD2 and FANCI are also post translationally
modified (PTM) through phosphorylation. It has been shown that FANCD2 is
phosphorylated by ATM (Ataxia-telangiectasia mutated) in response to ionizing
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radiation (IR). FANCD2 is also phosphorylated by ATR (ATM and Rad3-related) when
cells are treated with ICL inducing agents[13-15]. It is thought that DNA damage
dependent FANCD2 phosphorylation is key for its monoubiquitination and
heterodimerization with FANCI. ATM/ATR are also responsible for FANCI
phosphorylation. FANCI is phosphorylated in a DNA damage dependent manner on
six SQ/TQ residues that are proximal to its site of monoubiquitination [16]. The
phosphorylation of FANCI has been shown to function both upstream and downstream
of monoubiquitination [17, 18].
Though the main function of FANCD2 is in the DNA damage response (DDR),there is
evidence to show that it functions in other cellular processes. For example, FANCD2 is
critical in the resolution of RNA:DNA hybrids known as R-loops [19]. There is also
mounting evidence that suggests FANCD2 is involved in replication fork firing and
stability[20-22]. The recent Molecular Cell paper by Madireddy et al. showed that
FANCD2 is required for stability at common fragile sites (CFS) and that it may regulate
dormant origin firing under replication stress[23]. In addition to this, FANCD2 has been
shown to protect stalled replication forks from MRE11 degradation and, via its
interaction with CtBP-interacting protein (CtIP), it is involved in replication fork
restart[24, 25].
In this manuscript, I will present data that shows that FANCD2 is phosphorylated in a
DNA damage independent cell cycle dependent manner. This phosphorylation is at its
height during unperturbed S-phase of the cell cycle. Both in-silico and ex-vivo studies
done by our lab suggest that a cyclin dependent kinase (CDK) is responsible for this
phosphorylation. CDKs, along with their cyclin binding partners, are responsible for
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regulation of the cell cycle, halting it if damage is present[26]. There is precedent for
CDKs acting in the DDR, CDKs have been shown to phosphorylate BRCA1 and
BRCA2 (both of which are within the FA-BRCA pathway)[27-29]. We have identified
3 putative CDK sites that are proximal to the sites of monoubiquitination. Two mutants
have been created at these sites. One mutant cannot be phosphorylated (phospho-dead)
and the other mutant behaves as if it is constitutively phosphorylated, (a phosphomimetic). Surprisingly, it appears that the phospho-dead mutant is constitutively
monoubiquitinated while the phospho-mimetic is deficient in monoubiquitination.This
is at odds with the characterization of FANCI phosphorylation, in which
phosphorylation promotes monoubiquitination [16, 18]. Our data also suggests that
phosphorylation of FANCD2 may act as a “molecular switch” to activate other
functions, in particular its roles in DNA replication. Characterization of these
phosphorylation sites will shed light on the interplay between monoubiquitination and
phosphorylation, highlighting new roles for FANCD2 and the importance of temporal
regulation of monoubiquitination.

Results
Phosphorylation of FANCD2 is DNA damage independent and cell cycle
dependent
To elucidate whether FANCD2 phosphorylation was occurring in a DNA damage
independent manner a simple experiment was performed. U2OS cells were treated

51

Figure 1. FANCD2 is monoubiquitinated in a DNA damage independent cell cycle
dependent manner (A) U2OS cells were treat in the presence (+) or absence (-) of
200nMm MMC. The pellet was split in half, one half was treated for 2 hours with
lambda phosphatase (+) and the other was treated with phosphatase inhibitors (-). Blots
were probed with against FANCD2, FANCI and alpha-tubulin (B) HeLa cells were
blocked into late G1/S using a double thymidine block. The cells were released and time
points were taken every 2 hours for 16 hours. The pellet was then split in half and treated
with (+) and without (-) lambda phosphatase for 2 hours and immunoblotted against
FANCD2, FANCI, and Cyclin A. AS, asynchronous whole-cell lysate
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with and without the interstrand crosslinking agent mitomycin C (MMC). The lysates were
then split in half, half were treated with phosphatase inhibitors and the other half were
treated with lambda phosphatase. Lambda phosphatase cleaves phosphates off of serine,
threonine and tyrosine residues. We observed a prominent mobility shift between our
samples with and without lambda phosphatase. As is seen in lanes 1 and 2 of Figure 1A,
this shift occurred in the absence of any DNA damage. Of note, there was not a similar
shift in FANCI, signifying that FANCI is not as extensively phosphorylated as FANCD2.
To pinpoint where in the cell cycle phosphorylation is occurring, HeLa cells were used to
perform a double thymidine block, synchronizing cells in G1/S phase of the cell cycle. The
cells were then released and time points where taken every two hours for 16 hours. A
mobility shift between our untreated and lambda phosphatase treated samples was observed
within S-phase. This signifies the hyper-phosphorylation of FANCD2 in S-phase (Figure
1B).The cell cycle checkpoint protein Cyclin A was used as a control for cell cycle
progression, with its highest expression in late S early G2 of the cell cycle. Two important
observations can be made from this experiment. 1)

FANCD2 is extensively

phosphorylated in the absence of DNA damage 2) This phosphorylation occurs to the
largest degree during S-phase of the cell cycle.

FANCD2 phosphorylation is mediated by a cyclin dependent kinase
DNA damage independent phosphorylation of FANCD2 appears to be related to the cell
cycle. With this in mind, we began to look for candidate kinases that could be performing
this phosphorylation. Since we know the phosphorylation is cell cycle specific, we started
investigating cell cycle specific kinases. This led us to CDKs, CDKs are active during S54

Figure 2. FANCD2 is a potential substrate of CDK phosphorylation. (A) FA-D2 cells
stably expressing LacZ-V5 and FANCD2-V5 were immunoprecipitated with anti-V5
agarose and immune complexes were immunoblotted with anti-FANCD2 and anti-pSCDK.
(B) U2OS and U2OS cells stably expressing 3X FLAG FANCD2-WT were
immunoprecipitated with anti-FLAG agarose and immune complexes were immunoblotted
with anti-FANCD2, anti-FLAG, and anti-pSCDK. (C) U2OS 3X FLAG FANCD2
immunoprecipiated as shown in (B), was used for phospho enrichment and further mass
spectrometry analysis revealed several phosphorylated FANCD2 isoforms. X.laevis extract
FANCD2 was pulled down in a similar fashion to (A) and underwent mass spectrometry
analysis.
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phase of the cell cycle and, as previously stated, there is also precedence for CDKs
phosphorylating DDR proteins. Moreover, some of these proteins are in the FA-BRCA
pathway (BRCA1 and BRCA2) [26]. Two immunoprecipitations (IP) were performed to
determine if FANCD2 is a CDK substrate. The first was performed in an FA-D2 cell line,
cells lacking FANCD2, that stably express a FANCD2 construct with a C-terminal V5 tag
(FANCD2-V5). A vector containing V5 tagged LacZ was used as a control. FANCD2-V5
was immunoprecipitated using V5-agarose. The second was performed in U2OS cells,
transformed osteosarcoma cells, stably expressing 3xFLAG FANCD2 (FLAG-FANCD2).
An IP was performed using FLAG agarose. In both IPs, the pull down product was probed
with an antibody that recognizes serine residues phosphorylated by CDKs. The antibody
detected a FANCD2 band in both IPs (Figure 2A), suggesting that FANCD2 is a CDK
phosphorylation target. Mass spectrometry analysis of the U2OS 3xFLAG FANCD2 IP
showed a phosphorylation of FANCD2 at S692. In addition, our collaborator at the
University of Melbourne performed a similar experiment using X. laevis FANCD2 and
found a phosphorylation at S726 following mass spectrometry analysis (Figure 2B). These
both represent novel sites of phosphorylation.

FANCD2 contains a putative CDK cluster proximal to the site of monoubiquitination
The CDK consensus sequence is [S/T*]PX[K/R][30], however, there are examples of
proteins be phosphorylated by a CDK that only contain the S/P of the consensus sequence,
such as BRCA1[31]. When the FANCD2 amino acid sequence was analyzed
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Figure 3. FANCD2 contains a conserved putative CDK consensus site cluster. (A). A
Clustal Omega multiple sequence alignment of three putative CDK phosphorylation sites,
S525, S624, S726, in FANCD2 demonstrates strong evolutionary conservation. (B) Region
of the mouse Fancd2 crystal structure represented as both surface and ribbons with S/P
CDK consensus (teal) and the monoubiquitination site (yellow) indicated, using the
program Discovery Studio. (C) FA-D2 cells stably expressing empty, FANCD2-WT,-TA,
and -TD were incubated in the absence (-) and presence (+) of 250 nM MMC for 18 h, and
whole-cell lysates were immunoblotted with antibodies to FANCD2, V5, FANCI and αtubulin. The FANCD2-V5 and FANCI L/S ratios are the ratios of monoubiquitinated to
nonubiquitinated protein, and were calculated by measuring protein band intensities using
ImageJ image processing and analysis software (http://rsb.info.nih.gov/ij/).
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many putative CDK S/P sites were found (data not shown). To hone in on sites that might
have an effect on DNA repair, in-silico analysis was performed. When the sites are mapped
onto the mouse ID2 heterodimer (PDB ID:3S4W), human ID2 has yet to be crystallized,
we see that four of these sites are proximal to K562, the site monoubiquitination in mouse
fancd2 (Figure 3B). In addition, when a multi-species alignmentis performed using Clustal
Omega three of these sites, S525, S264 and S726, demonstrate strong evolutionary
conservation. The fourth sites was on an uncrystallized loop within mouse fancd2, we did
not recognize this site until much later so analysis of this site is ongoing. We hypothesized,
based on their proximity to K561, that the three identified sites were the most likely to have
an effect on FANCD2 monoubiquitination, based on their proximity to K561. Additionally,
two of these sites, S592 and S724, were found in the mass spectrometry results discussed
earlier. We next stably expressed two different V5-tagged FANCD2 mutants in a FA-D2
patient cell line. One mutant has S525, S264 and S726 mutated to alanines (TA), this
mutant is unable to be phosphorylated at these sites. The second mutant has the same
serines mutated to aspartic acids (TD), the negative charge on the aspartic acid acts as
phospho-mimetic (FANCD2 appears constitutively phosphorylated at these sites). V5
tagged wildtype (WT) FANCD2 and an empty vector were stably expressed as controls.
An experiment was performed in which each cell line was incubated with and without
MMC. When we immunoblotted, probing for FANCD2-V5, we found that the TA mutant
appeared to be constitutively monoubiquitinated while the TD mutant was deficient in
monoubiquitination (Figure 3C).
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Figure 4. Mutation of the FANCD2 CDK cluster alters both FANCD2 and FANCI
foci formation (A) FA-D2 cells + WT-V5, TA-V5 or TD-V5 were treated with and without
200 nM MMC or 0.8 μM APH. Cells were fixed and stained with a mouse polyclonal antiV5 antibody and counterstained with DAPI. At least 300 nuclei were scored per treatment
(B) FA-D2 cells + WT-V5, TA-V5 or TD-V5 were treated with and without 200nM MMC
or .8μM APH. Cells were fixed and stained with a rabbit polyclonal anti-FANCI antibody
and counterstained with DAPI. At least 300 nuclei were scored per treatment (C)
Representative images of foci images. DAPI is in blue, FANCD2-V5 is in red and FANCI
is in green. The merge is all three images overlaid
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Phosphorylation of FANCD2 plays an important role in foci formation
There is evidence to suggest that monoubiquitination of FANCD2 and aggregation within
the nucleus to form foci can be uncoupled, as seen in USP1 autocleavage mutants [32]. To
examine if this was occurring in our mutants, cells were treated with both MMC and
aphidicolin (APH), a known polymerase inhibitor and replication stressor[33]. The cells
were fixed and stained for FANCD2-V5, FANCI and DAPI. The TA mutants had
statistically significantly higher FANCD2-V5 and FANCI foci in the no treatment
condition than either WT or TD (Figure 4A, B). Upon treatment with both MMC and APH,
the TD mutant had statistically significant lower foci formation than either TA or WT. This
indicates that not only is the TA mutant deficient in monoubiquitination but FANCD2 is
unable to localize to the sites of damage within the nucleus. In addition, the TA mutant
seems to be constitutively monoubiquitinated and form foci even in the absence of damage.
It is noteworthy that the effects on foci formation also occurred in FANCI, indicating that
phosphorylation of FANCD2 does not increase the monoubiquitination of FANCI but does
increase its foci formation. This brings up questions about the importance of FANCD2
phosphorylation on FANCI-FANCD2 dimerization and aggregation within the nucleus.
FANCD2 phosphorylation effects chromosomal stability
One of the hallmarks of Fanconi Anemia is hypersensitivity to DNA damaging agents.
Chromosomal breakage analysis of peripheral blood samples treated with damaging
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Figure 5. The phospho-dead TA mutant has a high concentration of chromosomal
aberrations (A) Representative images of the types of chromosome aberrations including radial formations, telomere fusions, dicentrics, and complex aberrations observed in the TA mutant cells following .4µM APH treatment(B) FA-D2 cells + WTV5, TA-V5 or TD-V5 were treated with and without .4µM APH for 24 hours, fixed and
dropped onto slides and stained with giemsa. The slides were analyzed, counting aberration
such as radial formations, telomere fusions, dicentrics, and complex aberrations. This is
preliminary data; 50 metaphases were scored per condition
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agents are often used in clinical setting to diagnose FA[34]. We performed metaphase
spread analysis using our mutants, looking for chromosome gaps and breaks, dicentric
chromosome and more complex chromosome aberrations such as radials. When our
mutants were treated with low doses of APH, the TA mutant had a substantial increase in
damage over both the WT and TD. The TD had slightly lower amounts of damage than the
WT (Figure 6). Even though the TA mutant had both an increase in monoubiquitination
and foci formation, this did not correlate to decreased chromosomal aberrations and the
inverse seems to be true for the TD. We believe that this showcases the importance of
controlling the timing of FANCD2 monoubiquitination. It is detrimental to chromosomal
stability for FANCD2 to be constantly activated, FANCD2 monoubiquitination must be
precisely timed in order for proper DNA repair to take place.

Mutation of the FANCD2 CDK cluster impacts fork restart following damage
Our research has shown that FANCD2 is phosphorylated in S phase of the cell cycle and
that this phosphorylation occurs in the absence of any DNA damage. These are interesting
observations but they do not answer the basic question of what the purpose of this
phosphorylation is. Since this phosphorylation is specific to S-phase, the logical inference
is that the phosphorylation at these sites is somehow regulating FANCD2’s function in
DNA synthesis. To explore this, DNA strand analysis was performed to analyze both fork
restart following damage and the affects our mutations have on the total DNA synthesis
occurring. Cells were treated with 0.2 μM APH for 12 hours, pulsed for 20 minutes with
iodouridine followed by a 20 minute pulse with chlorouridine, these were stained red and
green respectively. In addition, a single strand antibody was used that stains the total DNA
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content of the cell. When these images are overlaid with the red/green images the percent
of active replication can be calculated (Figure S4). When analyzing the red and green
staining, we took the ratio of the red to the green. The length of the red portion represents
fork progression directly after DNA damage, while the green portion has fully recovered
and represents unperturbed synthesis. Without APH treatment there is a red:green ratio of
around 1, which should be expected since there is nothing to hinder the replication fork
(Figure 7A). APH treatment results in lower red:green ratios because the cells have to
recover from the treatment before progressing, however the TA mutant has a lower
red:green than either WT or TD (Figure 7A). This illustrates replication deficiencies in the
TA mutant, in particular where fork restart is concerned.
Interestingly, the TD maintained its red:green ratio of 1 and seemed almost unaffected by
the APH treatment. When the proportion of DNA that is actually replicating is analyzed
(Figure 7B), WT and TD seem to be completely unaffected by the APH treatment while
TA actually has a higher proportion of DNA replication following APH treatment. This
seemed counterintuitive to us until dormant origin firing was taken into account. When a
replication fork stalls, it is common for another origin to fire nearby to complete the
replication, this is termed dormant origin firing[35]. So based on the way in which we
analyzed the data, this would be counted as having a higher proportion of replicating DNA,
when in fact the total amount of DNA replicated would remain static and only the number
of origins would change.
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Figure 6 Phosphorylation of FANCD2 facilitates fork restart and stability (A) FA-D2
cells + WT-V5, TA-V5 or TD-V5 were treated with and without .2µM APH for 12 hours,
then pulsed for 20 minutes with iodouridine (red) followed by a 20 minute pulse with
cholouridine (green). The thymidine analogs were stained and visualized. 50 strands were
analyzed per condition. (B) The cells were treat as in (A) with the addition of a ssDNA
antibody, this will stain every strand of DNA present. The total number strands undergoing
active DNA replication, red/green staining, was divided by the total number of DNA
strands present. This is preliminary data; at least 100 strands were analyzed per condition.
(C) Representative images of strands analyzed per condition per cell type. The first pulse,
iodouridine, is in red the second pulse, chlorouridine, is in green. (D) Representative
images of ssDNA antibody and IdU/CldU staining with overlays.
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Discussion
In this study, we have shown that FANCD2 is extensively phosphorylated during S-phase
of the cell cycle. We have also presented data showing that this phosphorylation is DNA
damage

independent.

Both

our

FANCD2-V5

and

FANCD2-3XFLAG

immunoprecipitations suggest that a CDK is responsible for this phosphorylation, a result
also supported by mass spectrometry.. When we examine the mobility shift that is present
when FANCD2 is treated with lambda phosphatase, we see that this shift must be from the
hyper-phosphorylation of FANCD2 (a single phosphate weighs ~80 daltons and our
phosphate shift is 2-3 kilodaltons). This shift is not present in FANCI even upon the
addition of MMC, signifying that FANCD2 is more extensively phosphorylated than
FANCI. It has been shown that both FANCD2 and FANCI are phosphorylated by the DNA
damage kinases ATM/ATR, this is dependent on DNA damage[13, 14]. Our data suggest
that a CDK may also be acting in the pathway to regulate FANCD2 function independent
of DNA damage. There is precedent for CDKs phosphorylating DDR protein however it is
unique for them to have a DDR protein substrate in the absence of DNA damage.
When the CDK cluster was mutated to alanine (TA mutant) or aspartic acids (TD mutant)
we gained insight into the functional significance of these phosphorylations. It appears that
phosphorylation at these sites lowers the overall concentration of monoubiquitinated
FANCD2 within the cell ,while inhibiting phosphorylation increases monoubiquitination.
This is the inverse of FANCI, where phosphorylation has been shown to promote
monoubiquitination[16, 18]. The phospho-dead TA mutant was also able to form foci in
the absence of damage while the TD mutant was deficient in foci formation even in the
presence of DNA damage. We had expected that constitutive monoubiquitination of
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FANCD2 may have decreased DNA damage by promoting ICL repair and HR, however,
this was not the case. Through chromosomal breakage analysis we see that the TA mutant
has higher amounts of damage than either WT or TD and TD had levels of damage slightly
lower than WT. When we examined the effects that the mutants had on DNA synthesis,
the TA had trouble recovering from APH treatment and appeared to have more active
replication occurring, we believe that this is due to dormant origin firing. The TD appeared
to be unaffected by damage and continued DNA replication unperturbed.
FANCD2 has been shown to be involved in DNA replication in several recent studies[20,
21, 22]. In particular, the recent paper by Madireddy et al. highlights the role of FANCD2
in replication across common fragile sites. They state that FANCD2 is important for
replication fork stability and efficient replication initiation at these large repeat rich
genomic regions[23]. We propose that FANCD2 phosphorylation at these sites acts a
“molecular switch” to alter its function from ICL repair to replication fork maintenance.
This is supported by both our chromosomal breakage and DNA fiber analysis. Even with
high levels of monoubiquitination the TA mutant has extensive chromosomal aberrations
and slower fork restart following APH treatment. Since the TA cannot be phosphorylated,
it cannot switch roles from ICL to fork maintenance, this results in fork collapse and DNA
damage. Upon replication stress it is essential for FANCD2 to be able to switch functions
and prevent fork collapse and DNA double strand breaks.
The mechanism by which phosphorylation of this CDK cluster promotes FANCD2’s role
in replication fork stability is still under investigation, however, we can speculate as to how
it is occurring. One possibility, which has been proposed and studied by other groups, is
that FANCD2 arrives at points of instability within the genome, such as CFS, and works
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to resolve R-loops at these sites[19, 23]. It is well documented that R-loops occur with a
higher frequency during DNA replication and the transcription of genes especially under
replication stress; FANCD2 has been shown to resolve R-loops in both murine and human
models[19, 36]. Phosphorylation of this CDK cluster may block monoubiquitination of
FANCD2 and promote its role in R-loop resolution, which would increase the stability of
stressed replication forks. It is also possible that by blocking the monoubiquitination of
FANCD2, through phosphorylation, we are allowing FANCD2 to be recruited to
replication forks and recruit enzymes that prevent fork collapse. Recent evidence points to
fanconi associated nuclease 1 (FAN1) as a candidate for this function. FAN1 has been
shown to prevent replication fork progression upon fork collapse, thereby preventing DNA
damage, this is a completely separate function from its roles in ICL repair[9, 37]. It is
known that FAN1 associates with FANCD2 at ICLs, a similar association could occur at
replication forks to halt the fork upon collapse and prevent any DNA damage.
Our mutants will be key in picking apart the mechanism and function of this novel CDK
cluster within FANCD2. We still need to do further analysis to answer some key questions
such as 1) Does this phosphorylation inhibit FANCD2 monoubiquitination or promote its
deubiquitination? 2) Which CDK is responsible for this phosphorylation? 3) How does this
phosphorylation promote fork restart and prevent chromosomal aberrations? Given that
CDK inhibitors are in clinical use and that over 90% of FA patients are deficient in
FANCD2 monoubiquitination, answering these questions could reveal unexplored
treatment opportunities for patients
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Figure 7. A model of the effects of FANCD2 phosphorylation. This model illustrates
the effects on FANCD2 function following phosphorylation of this putative CDK cluster.
Upon phosphorylation, left panel, FANCD2 cannot be monoubiquitinated. This promotes
its recruitment to stalled replication forks, depicted with red bars, and either through Rloop resolution or FAN1 recruitment the fork is restarted, depicted with green arrows. If
FANCD2 is not phosphorylated, right panel, then it will go forward with its canonical
function in ICL.
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Plasmids, site-directed mutagenesis, and transient transfections
The full length FANCD2 cDNA sequences were TOPO cloned into the pENTR⁄D-TOPO
(Invitrogen) entry vector, and subsequently recombined into the pLenti6.2/V5-DEST
(Invitrogen) destination vector and used to generate lentivirus for the generation of stable
cell lines. The TA and TD cDNA were generated by site-directed mutagenesis of the wild
type FANCD2 cDNA using the Quikchange Site-directed Mutagenesis Kit (Stratagene).
The forward and reverse oligonucleotide sequences used are as follows: TA: S726A-FP 5’AGGCCAAAAATTGGTGGCTCCGCTGTGCCTGGC-3’,

S624A-FP

5’-

TCCTGCAGTGAGCAGGCTCCTCAGGCCTCTGCAC-3’,

S525A-FP

5’-

CTGGATAACATAGCCCCTCAGCAAATACGAAAACTCTTCTATGTTCTCAGCAC
-3’; S726A-RP 5’- GCCAGGCACAGCGGAGCCACCAATTTTTGGCCT-3’, S624ARP 5’- GTGCAGAGGCCTGAGGAGCCTGCTCACTGCAGGA-3’, S525A-RP 5’GTGCTGAGAACATAGAAGAGTTTTCGTATTTGCTGAGGGGCTATGTTATCCAG
-3’.

TD:

S726D-FP

5’-AGGCCAAAAATTGGTGGATCCGCTGTGCCTGGC-3’,

S624D-FP 5’- TCCTGCAGTGAGCAGGATCCTCAGGCCTCTGCAC-3’, S525D-FP
5’CTGGATAACATAGACCCTCAGCAAATACGAAAACTCTTCTATGTTCTCAGCAC
-3’; S726D-RP 5’-GCCAGGCACAGCGGATCCACCAATTTTTGGCCT-3’, S624D-RP
5’-

GTGCAGAGGCCTGAGGATCCTGCTCACTGCAGGA-3’,

S525D-RP

5’-

GTGCTGAGAACATAGAAGAGTTTTCGTATTTGCTGAGGGTCTATGTTATCCAG
-3’.
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Lambda phosphatase assay
Cells were harvested and pellets were split into two, lysed in either lambda phosphatase
lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1 mM EGTA, 1 mM dithiothreitol,
2 mM MnCl2, 0.01% Brij35, 0.5% NP-40, and protease inhibitor) or lambda phosphatase
buffer with the addition of phosphatase inhibitors, 2 mM Na₃VO₄ and 5 mM NaF for 15
min at 4oC followed by sonication for 10 s at 10% amplitude using a Fisher Scientific
Model 500 Ultrasonic Dismembrator. Whole-cell lysates were incubated with or without
30 U of lambda phosphatase 2 h at 30°C, or for the times indicated. Proteins were resolved
on NuPage 3-8% w/v Tris-Acetate, 4-12% w/v Bis-Tris gels (Invitrogen), or 6% SuperSep
Phos-tag (Wako Pure Chemical Industries) and transferred to polyvinylidene difluoride
(PVDF) membranes. Larger proteins were resolved for 5 h on ice.
Cell-cycle synchronization
HeLa cells or the indicated mutants were synchronized by double thymidine block method.
Cells were treated with 2.5 mM thymidine for 18 hours, thymidine-free media for 10 hours,
and 2.5 mM thymidine for 18 hours to arrest the cell cycle at G1/S. Cells were washed
twice with phosphate-buffered saline (PBS) and released in DMEM + 12% FBS, Lglutamine, and penicillin/streptomycin and analyzed at various time intervals by lambda
phosphatase assay and immunoblotting, or flow cytometry
Immunoprecipitation
FA-D2 + LacZ, FA-D2 + FANCD2-V5, U2OS, and U2OS 3XFLAG FANCD2 cells were
lysed in Triton-X lysis buffer (50 mM Tris.HCl pH 7.5, 1% v/v Triton X-100, 200 mM
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NaCl, 5mM EDTA, 2mM Na3O4V, Protease inhibitors (Roche), and 0.153g Bglycerophosphate) on ice for 15 min followed by sonication for 10 s at 10% amplitude
using a Fisher Scientific Model 500 Ultrasonic Dismembrator. V5 or FLAG-agarose were
washed and blocked with NETN100 (20 mM Tris-HCl pH 7.5, 0.1% NP-40, 100 mM NaCl,
1 mM EDTA, 1 mM Na3O4V, 1 mM NaF, protease inhibitor (Roche)) + 1% BSA and the
final wash and resuspension was done in Triton-X lysis buffer. Lysate was then incubated
with appropriate agarose at 4°C for 2 h, nutating. Beads were then washed in Triton-X lysis
buffer and boiled in 1× NuPAGE buffer (Invitrogen) and analyzed for the presence of
proteins by SDS-PAGE and immunoblotting or stained using Colloidal Blue Staining Kit
(Invitrogen) for mass spectrometry.
Antibodies and immunoblotting
For immunoblotting analysis, cell pellets were washed in PBS and lysed in 2% w/v SDS,
50 mM Tris-HCl, 10 mM EDTA followed by sonication for 10 s at 10% amplitude using
a Fisher Scientific Model 500 Ultrasonic Dismembrator. Proteins were resolved on NuPage
3-8% w/v Tris-Acetate or 4-12% w/v Bis-Tris gels (Invitrogen) and transferred to
polyvinylidene difluoride (PVDF) membranes. The following antibodies were used: rabbit
polyclonal antisera against FANCD2 (NB100-182; Novus Biologicals), FANCI (A301254A, Bethyl), and pS CDK (9477, Cell Signaling), RPA (NA18, Calbiochem), FLAG
(F7425, Sigma),and mouse monoclonal sera against α-tubulin (MS-581-PO, Neomarkers),
cyclin A (SC751, Santa Cruz), and V5 (13202, Cell Signaling).
Cell culture
HeLa, U2OS, U2OS 3X FLAG FANCD2 cells were grown in Dulbecco's modified Eagle's
medium

(DMEM)

supplemented

with
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12%

v/v

FBS,

L-glutamine

and

penicillin/streptomycin. 066 and PD7L cells were grown in Roswell Park Memorial
Institute medium (RPMI) supplemented with 18% v/v FBS, L-glutamine and
penicillin/streptomycin. 293FT viral producer cells (Invitrogen) were cultured in DMEM
containing 12% v/v FBS, 0.1 mM non-essential amino acids (NEAA), 1% v/v L-glutamine,
1 mM sodium pyruvate and 1% v/v penicillin/streptomycin. PD20 FA-D2 (FANCD2hy/-)
cells were purchased from Coriell Cell Repositories (Catalog ID GM16633). These cells
harbor a maternally inherited A-G change at nucleotide 376 that leads to the production of
a severely truncated protein, and a paternally inherited missense hypomorphic (hy) mutation
leading to a R1236H change [38]. To generate stable lines expressing wild type or mutant
FANCD2, FA-D2 cells were infected with pLenti6.2-FANCD2 (Invitrogen) lentivirus,
followed by selection in DMEM supplemented with 15% v/v FBS, L-glutamine,
penicillin/streptomycin and 2 μg/ml blasticidin.
Immunofluorescence microscopy
For immunofluorescence microscopy (IF) analysis, cells were seeded in 4-well tissue
culture slides (BD Falcon) in the presence or absence of drug(s) for 24 h. Soluble cellular
proteins were pre-permeabilized with 0.3% v/v Triton X-100 and cells were fixed in 4%
w/v paraformaldehyde and 2% w/v sucrose at 4°C followed by permeabilization in 0.3%
v/v Triton X-100 in PBS. Fixed cells were blocked for 30 minutes in antibody dilution
buffer (5% v/v goat serum, 0.1% v/v NP-40, in PBS) and incubated with primary antibody
for 1 h. Cells were washed three times in PBS, as well as permeabilization buffer, and
incubated for 30 min at room temperature with an Alexa Fluor 488-conjugated or Alexa
Fuor 594 secondary antibody and the slides were counterstained and mounted in
vectashield

plus

4’6-diamidine-2-phenylindole
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dihydrochloride

(DAPI)

(Vector

Laboratories). Nuclear foci were scored using a Zeiss AxioImager.A1 upright
epifluorescence microscope with AxioVision LE 4.6 image acquisition software. Primary
antibodies used for IF were anti-v5 (18870-01; QED Biosciences Inc.), anti-FANCI (A300212A; Bethyl Laboratories. Statistical significance was determined using paired two-tailed
Student’s t-test analysis.
Chromosome breakage
For chromosome breakage assays, cells were incubated in the absence or presence of .4µM
APH for 18-24 h. Prior to harvesting, cells were treated with 0.1 µg/ml Colcemid
(Gibco/Invitrogen) for 2 h. Cell pellets were incubated in 0.075 M KCl at 37°C for 18 min,
followed by fixation in Carnoy’s fixative (3:1 methanol:glacial acetic acid) with multiple
changes. Cells were dropped onto chilled slides and air-dried prior to staining with 2.5%
w/v Giemsa solution (Sigma). Metaphases were analyzed using a Zeiss AxioImager.A1
upright epifluorescent microscope with AxioVision LE 4.6 image acquisition software.
DNA fiber analysis
For chromosome breakage assays, cells were incubated in the absence or presence of .2µM
APH for 12 h. The APH media was removed and media containing 30μM
iodouridine(sigma;, this media was removed and the cells were treated with 30µM
chloropuridine. Cells were harvested pelleted and the total genomic DNA was purified.
The DNA was “stretched” on glass silane coated slides (sigma; S4651-72EA) using a
Corning cover glass. The coverslip was then treated with three primary antibodies, against
iodouridine, chlorouridine and a ssDNA antibody. A secondary antibody with an attached
fluorophore was used against each primary. These slides were mounted using
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VECTASHIELD Antifade mounting medium (Vector labs: H-1200). These were then
visualized on a Zeiss fluorescence to monitor IdU/CldU nucleoside incorporation.
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Conclusion
Monoubiquitination of FANCD2 is essential for the function of FA-BRCA pathway. It is
this activating step that is absent in over 90% of FA patients. Though it is a critical step
within the pathway, there are still long standing questions about its function. Why is
FANCD2 monoubiquitinated? What is the function of this post translational modification?
What purpose does this monoubiquitination serve in ICL repair? These are key question,
the answers to which will provide much needed insight into the pathogenicity of this
disease. It is known that FANCD2 is necessary for chromosomal stability and that defects
in monoubiquitination inhibit the downstream proteins from completing HR mediated ICL
repair. In order to understand the purpose of this monoubiquitination we must first
understand the right environment and conditions that facilitate it. This dissertation lays out
a framework for this understanding, first examining monoubiquitination at the chromatin
level and then at the protein level.
At the chromatin level we attempted to understand what effects changes to chromatin
architecture via histone modifications would have the FA-BRCA pathway. To accomplish
this we first look at histone methylation, typically resulting in a closed chromatin structure.
We found that certain marks, namely H3K27me3, if inhibited had a drastic effect on
FANCD2 monoubiquitination. Inhibition of this mark greatly increased FANCD2
monoubiquitination and foci formation in the absence of any DNA damage. This effect
was shown to be mediated by the PRC2 component EZH2. Additionally, we performed
tests to see if inhibiting the deacetylation of histones, which should open up chromatin,
would have the opposite effect. To our surprise, this was not the case. FANCD2 had lower
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levels of monoubiquitination in the presence of HDAC inhibitors. This was thought to be
because of the biphasic nature of histone acetylation and deacetylation, being rapidly
acetylated and deacteylated. These results highlight the importance of the chromatin
environment in DNA repair.
At the protein level we looked at FANCD2 phosphorylation. We were able to show that
FANCD2 is extensively phosphorylated in a DNA damage independent manner. These
phosphorylations were shown to be cell cycle dependent. Through immunoprecipitation
studies, it was found that a CDK is mediating this PTM. In-silico analysis revealed a
puatative CDK phospho cluster proximal to the site of monoubiquitination in FANCD2.
Upon mutation of this cluster, to either a phospho-dead (TA) or phospho-mimetic (TD)
mutant, differences in monoubiquitination levels were observed. The TA was
constitutively monoubiquitinated while the TD could not be monoubiquitinated even in the
presence of damage. The TA also had high levels of foci formation while the TD was
unable to form foci. The TA mutant had large amounts of chromosomal abnormalities and
trouble with fork restart following damage, the opposite was true for the TD mutant. It
seems as if the phosphorylation of FANCD2 at this CDK cluster is facilitating blocking
FANCD2 monoubiquitination and promoting its roles in replication fork stability. This data
showed how vital proper timing of monoubiquitination is in DNA repair
This dissertation demonstrates how complicated and multifaceted ICL repair is. Not only
do you need to have an accommodating chromatin environment but it is necessary that the
protein itself be modified in the right fashion for proper repair to take place
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DNA double-strand breaks (DSBs) can arise through exposure to exogenous DNA damaging agents
such as ionizing radiation, as well as through endogenous means; for example, via DNA replication
fork collapse. Irrespective of the source, the physical severing of the sugar-phosphate backbone
represents an acute threat to organismal viability and genome stability. Hanahan and Weinberg
describe genome instability and mutation as an enabling characteristic of cancer.1 Indeed,
chromosome structural rearrangements, which are pervasive in cancer, invariably arise from DSB
repair gone awry. To deal with this threat, all cells have evolved 2 principal means to repair DSBs:
homologous recombination (HR) and nonhomologous DNA end joining (NHEJ). HR is
predominantly a conservative and error-free process, employing a homologous template, usually
the sister chromatid, to repair the break. RAD51, the eukaryotic ortholog of bacterial RecA, is the
major HR protein. Conversely, NHEJ is typically error-prone, and rejoins the break without regard
for the state of the ends, often resulting in loss of nucleotides or the re-joining of noncontiguous
ends. Exemplifying the importance of HR, many key tumor suppressor genes encode central HR
players, e.g. BRCA1 and BRCA2. Furthermore, several genetic diseases characterized by increased
cancer risk are caused by mutations in HR genes, one example of which is Fanconi anemia (FA).
FA is clinically characterized by congenital defects, bone marrow failure, and increased cancer
risk.2 FA is caused by mutation of any one of 20 known genes, which encode proteins that function
cooperatively in the FA-BRCA pathway to promote HR.3 The molecular links between FA and
HR are an area of active investigation. Evidence presented in this volume of Cell Cycle points to a
novel noncanonical connection between enzymes involved in the major regulatory step of the FABRCA pathway and a key HR effector.4 This regulatory step is the site-specific monoubiquitination
of the FANCD2 and FANCI proteins. The E2 ubiquitin-conjugating enzyme FANCT/UBE2T and
the E3 ubiquitin ligase FANCL catalyze the forward step of this reaction. The reverse step deubiquitination - is catalyzed by the USP1 deubiquitinating enzyme (DUB) and its heterodimeric
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Figure 1. Speculative schematic of the role of the USP1-UAF1-RAD51AP1 complex
in HR. UAF1 binds to USP1through its WD40 domain, and RAD51AP1 through its SLD1/
2 domains. In the absence of either UAF1 or USP1, RAD51AP1 is degraded by the
proteasome. Following RAD51 nucleofilament formation, RAD51AP1 is required for
synaptic complex and D-loop formation. This is promoted by the presence of UAF1,
however the role of USP1 in this process remains unclear. On the right side of this figure,
USP1 is depicted in gray font to signify its uncertain role in this process.
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binding partner UAF1.5,6 In a large-scale global proteomic screen of DUB-interacting networks,
Sowa et al. previously determined that the USP1- UAF1 heterodimer interacts with the RAD51AP1
protein.7 RAD51AP1 is a vertebrate specific accessory factor for RAD51 that promotes the
assembly of the synaptic complex and D (displacement)-loop, key HR intermediate structures (Fig.
1). However, the functional significance of this interaction was not examined. In the accompanying
Cell Cycle manuscript, Cukras et al. have tackled this important question.4 The authors verified
this interaction and, by depleting UAF1 using siRNA, established that the interaction between
USP1 and RAD51AP1 is UAF1-dependent. The authors also established that the UAF1 WD40
repeats as well as its SUMO-like domains (SLDs) are necessary for RAD51AP1 binding. Previous
studies had demonstrated that USP1 regulates the stability of the ID (inhibitor of DNA binding)
proteins. Similarly, Cukras et al. show that depletion of USP1 or UAF1 leads to destabilization of
RAD51AP1. Cukras et al. next sought to map the region of RAD51AP1 that binds to UAF1. Serial
truncations and mutagenesis analysis established that residues D133-L137 are required for efficient
RAD51AP1-UAF1 binding. Accordingly, deletion of this UAF1 binding region (DDYLDL)
resulted in decreased RAD51AP1 stability, supporting the theory that USP1-UAF1-RAD51AP1
form a stable protein complex. Interestingly, mutation of RAD51AP1 K139, previously shown to
be a site of ubiquitination, did not affect interaction with UAF1. To explore the functional
significance of the RAD51AP1-UAF1 interaction, Cukras et al. expressed wild type or
RAD51AP1-DDYLDL in U2OS cells depleted of endogenous RAD51AP1. In contrast to wild type
RAD51AP1, the DDYLDL mutant failed to correct cellular ICL sensitivity. Furthermore,
RAD51AP1-DDYLDL expressing cells exhibited persistent DNA damage-inducible RAD51
nuclear foci, suggesting that the USP1-UAF1-RAD51AP1 complex may promote the efficient and
timely resolution of a key HR intermediate structure. A recent complementary study in Cell Reports
by Liang et al. provides further insight into the functional significance of the RAD51AP1-UAF1
interaction.8 Similar to Cukras et al., Liang et al. establish that the UAF1 SLDs mediate interaction
with RAD51AP1. While mutation of these SLDs compromises interaction with RAD51AP1, these
93

mutants are proficient forinteraction with USP1 and stimulation of its DUB activity toward
FANCD2. Importantly, Liang et al. also establish that UAF1 alone stimulates the ability of
RAD51AP1 to promote synaptic complex and D-loop formation in vitro, and this
stimulation depends on the formation of the RAD51AP1-UAF1 complex. These assays
indicate that UAF1-stimulated RAD51AP1 activity is largely USP1-independent. While
Cukras et al. clearly show that USP1 forms a complex with UAF1 and RAD51AP1, a role
for enzymatic deubiquitination has not been established. Taken together, these studies
reveal a novel and critical function for UAF1 in promoting HR that appears to be
independent of USP1 deubiquitinating activity. However, it remains to be determined how
RAD51AP1 is removed from RAD51 nucleoprotein filaments enabling the dissolution of
HR intermediates – ubiquitination remains a plausible mechanism. In conclusion, these
studies uncover important mechanistic insight into the molecular biology of HR and FA
and suggest the existence of more FA genes linked to the regulation of RAD51 function.
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Supplemental information for Manuscript-I “Modulation of the fanconi anemia pathway
via chemically induced changes in chromatin structure”
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Supplementry Figure 1: The HMTi BRD4770 induces FANCD2 nuclear foci
formation. (A) U2OS and (B) BJ-TERT cells were incubated in the absence (NT) or
presence of 10 μM BRD4770, 5 μM GSK-J1, and 2.5 μM BIX01294, with (+) and without
(-) 200 nM MMC for 24 h. Cells were fixed and stained with rabbit polyclonal antiFANCD2 antibody (green) and counterstained with DAPI (blue), and the number of nuclei
with >5 FANCD2 foci were scored. At least 300 nuclei were scored for each treatment and
this experiment was performed at least three times with similar results. Error bars represent
the standard errors of the means from three independent experiments. (C) BRD4770
treatment leads to changes in the staining pattern of the heterochromatin marker HP1ɑ.
U2OS cells were incubated in the absence (NT) or presence of 10 μM BRD4770 for 24 h.
Cells were fixed and stained with rabbit polyclonal anti-FANCD2 antibody (green), mouse
monoclonal anti-HP1ɑ antibody (red), and counterstained with DAPI (blue).
Representative images from two independent experiments are shown.
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Supplementry Figure 2: BRD4770-induced activation of the FA pathway does not
occur via the direct induction of DNA damage. U2OS cells were incubated with (+) and
without (-) 200 nM mitomycin C (MMC) in the absence (NT) or presence of 10 μM
BRD4770 for 24 h. Cells were fixed and stained with mouse monoclonal anti-γH2AX
antibody and counterstained with DAPI, and the number of nuclei with >10 γH2AX foci
were scored. At least 300 nuclei were scored for each treatment and this experiment was
performed three times with similar results. Error bars represent the standard errors of the
means from three independent experiments.
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Supplementry Figure 3: BRD4770-induced activation of the FA pathway may occur
via inhibition of the PRC2 complex. (A) U2OS cells were incubated in the absence (NT)
or presence of the indicated concentrations of BRD4770 or BIX01338 for 24 h. Whole-cell
lysates were prepared and immunoblotted with anti-FANCD2, anti-FANCI, and anti-ɑTubulin antibodies. (B) U2OS cells were incubated with the indicated concentrations of
BRD4770 and DZNep for 4 and 8 days. Whole-cell lysates were prepared and
immunoblotted with anti-EZH2 and anti-ɑ-Tubulin antibodies. L:S Ratio, ratio of
monoubiquitinated to nonubiquitinated FANCD2; or FANCI RBI, relative band intensity.
(C) U2OS cells were incubated with 10 μM BRD4770 or the indicated concentrations of
DZNep or UNC0646 for 24 h. Cells were fixed and stained with rabbit polyclonal antiFANCD2 antibody and counterstained with DAPI, and the number of nuclei with >5
FANCD2 foci were scored. At least 300 nuclei were scored for each treatment and this
experiment was performed three times with similar results. Error bars represent the
standard errors of the means from three independent experiments. *, P < 0.05; **, P < 0.01;
***, P < 0.001, with comparison to untreated cells. (D and E) HCT116 p53+/+ and p53-/(D) and HeLa (E) cells were incubated in the absence or presence of the indicated
concentrations of BRD4770 for 24 h (D) or 24, 48, or 72 h (E). Whole-cell lysates were
prepared and immunoblotted with the indicated antibodies. L:S Ratio, ratio of
monoubiquitinated to nonubiquitinated FANCD2; or FANCI RBI, relative band intensity.
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Supplementry Figure 4: Activation of FANCD2 monoubiquitination following
treatment with the EZH2 inhibitor EPZ-6438. MCF10A cells were treated with the
indicated concentrations of the EZH2-specific inhibitor EPZ-6438 for 24 h. Cells were
fixed and stained with rabbit polyclonal anti-FANCD2 antibody and counterstained with
DAPI, and the number of nuclei with >5 FANCD2 foci were scored. At least 300 nuclei
were scored for each treatment and this experiment was performed twice with similar
results. Error bars represent the standard errors of the means from two independent
experiments. *** P < 0.001, with comparison to untreated cells.
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Supplementry Figure 5: Chemical structures of the inhibitors and DNA damaging
agents used throughout this study. (A) Histone methyltransferase inhibitors, (B) histone
demethylase inhibitors. (C) histone deacetylase inhibitors, and (D) miscellaneous DNA
damaging agents.
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